Abstract. Combination therapy with interferon (IFN)-· and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucidated. We examined the molecular events underlying the antiproliferative effects of IFN-· and 5-FU in combination using six human HCC cell lines. When the antiproliferative effects of administering IFN-· and 5-FU together were analyzed using isobolograms, we found that the cell lines could be divided into two groups: the S-group containing three cell lines, which showed synergistic effects, and the A-group, containing the remaining three cell lines, which showed additive effects. Real-time RT-PCR and Western blot analyses revealed that the expression levels of type I IFN receptor subunits, IFNAR1 and IFNAR2, were specifically up-regulated by 5-FU in all three cell lines of the S-group with the exception of IFNAR2 in one cell line, but not in those of the A-group. IFN-· modulated the protein expression levels of six enzymes regulating sensitivity to 5-FU, but none of them were down-or up-regulated in the same way in all members of the S-or A-group. In conclusion, the 5-FUinduced modulation of IFN receptor expression could play a pivotal role in the therapeutic efficacy of IFN-· combined with 5-FU. Measuring the expression levels of IFN receptors, and their ability to be up-regulated, may be a promising method for selecting HCC patients for this type of combination therapy.
Introduction
Hepatocellular carcinoma (HCC), the most common primary liver cancer, is one of the most frequent and aggressive malignant tumors, and its incidence is increasing. The surgical resection of hepatic lesions is the most effective treatment for patients with HCC, and local therapeutic approaches, such as transcatheter arterial embolization (1), percutaneous transhepatic ethanol injection (2) , microwave coagulation (3), and radiofrequency ablation (4) have also been reported to be effective. However, these therapies are still not effective for patients with advanced HCC, who are often not suitable for surgery and whose 5-year survival rate is extremely low (5) . One chemotherapeutic strategy is combined chemotherapy with 5-fluorouracil (5-FU) and interferon (IFN)-·. Monden and colleagues have reported a beneficial therapeutic effect in a patient with recurrent HCC and multiple lung and bone metastases (6) (7) (8) . However, this combined treatment was accompanied by increased toxicity, as manifested by an elevated incidence of mucositis and neurological and hematological side effects (9) . It is therefore important to understand the exact mechanism of this combination therapy so that patients likely to respond can be selected and unnecessary side effects can be avoided.
5-FU has two major antitumor mechanisms: one involves its active metabolite 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), inhibiting the activity of thymidylate synthase (TS) and consequently DNA synthesis; the other is related to the incorporation of 5-FU metabolite into RNA and DNA, thereby disrupting normal RNA processing and function. The sensitivity of cancer cells to 5-FU is often influenced by the enzymes affecting 5-FU metabolism, including dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), uridine phosphorylase (UP), and thymidine kinase (TK). In contrast, IFNs are divided into type I and type II. The human type I IFN family is composed of at least 14 structurally related IFN-· subtypes and single IFN-ß and IFN-ˆsubtypes. Type I IFNs have various biological activities, including antiviral, anti-proliferative, immunomodulatory (10) (11) (12) , and antiangiogenic effects (13, 14) , mediated by the type I IFN receptor. This receptor is composed of two functional transmembrane subunits, type I IFN receptor subunit 1 (IFNAR1) and subunit 2 (IFNAR2), cooperating to form a high-affinity receptor for all type I IFNs (15, 16) . IFNAR2 is the major binding subunit and IFNAR1 is necessary for the tight binding. Of these receptor molecules, the expression levels of the type I IFN receptor were closely correlated with the response rates to IFN treatment in patients with chronic hepatitis C (17) , and overexpression of the IFNAR2 markedly increased the antiproliferative activity of IFNs and their capacity to induce apoptosis (18) , suggesting that the type I IFN receptor is a key molecule for the antitumor activity of IFN-·.
Concerning possible mechanisms behind IFN-· and 5-FU showing improved therapeutic efficacy, increased FdUMP concentrations, decreased protein level of TS, an increase in TS inhibition rate and TP activity, and an alteration in 5-FU pharmacokinetics by combined IFN-· have been reported (19) (20) (21) (22) (23) (24) . Eguchi et al have reported that augmentation of the antitumor effect of 5-FU by IFN-· might in part be attributable to the up-regulation of p27
Kip1 blocking cell cycle progression (25) . However, none of these theories provide a consistent mechanism for the exact rationale of this combination therapy. Furthermore, almost all studies have assumed that IFN-· plays a role in modulating the antitumor activity of 5-FU.
In this study, we provide evidence that the modulation of IFN receptor expression by 5-FU is specifically associated with the improved efficacy rather than the cellular modulation of the enzymes that regulate the sensitivity to 5-FU by IFN-·.
Materials and methods
Drugs. Natural human IFN-· was purchased from Otsuka Pharmaceutical Co., Ltd. (OIF, Tokyo, Japan) and 5-FU was purchased from Kyowa Hakko Kogyo Co., Ltd. (5-FU Injection 250 Kyowa, Tokyo, Japan).
Cell lines. HCC cell lines, KIM-1, KYN-1, KYN-2, KYN-3, HAK-1A and HAK-1B (26) (27) (28) (29) (30) , were grown in Dulbecco's modified Eagle's medium (Nissui Seiyaku Co., Tokyo, Japan) with 10% fetal bovine serum (FBS) (FETALCLONE III, Hyclone, UT, USA) in a humidified atmosphere of 5% CO 2 at 37˚C.
Antiproliferation test. Cells were seeded into 96-well plates at 1,000 cells/0.1 ml/well and incubated overnight. On the following day, 100 μl aliquot containing IFN-· and 5-FU was added and cultured for a further 5 days. In study of scheduledependent synergy, HCC cells were seeded into 12-well plates at 5,000 cells/1 ml/well. On the following day, 1-ml aliquot containing drugs was added. After a further 3 days, culture medium was exchanged for fresh medium including another drug and cultured for a further 3 days. The number of viable cells was estimated by activity of cellular dehyrogenases using WST-8 reagent (Cell Counting Kit-8, DOJINDO, Kumamoto, Japan) (31) .
Isobologram analysis.
To analyze the mode of interaction between 5-FU and IFN-·, the combined doses that reduced cell growth by 50% were plotted as isobolograms, according to the method of Steel and Peckham (32) . The envelope of additivity surrounded by mode I (heteroaddition), IIa and IIb (isoaddition) curves, was constructed based on the doseresponse curves of IFN-· and 5-FU alone. Thus, when the data points for the combined drugs fell within this envelope, the combined effect was judged to be additive. When the points fell in the area under the envelope of additivity, the combined effect was judged as synergistic, because in this case, 50% inhibition was produced by a lower concentration than predicted on an additive basis.
cDNA preparation and quantitative real-time RT-PCR. Total RNA was extracted using Isogen (Nippon Gene Co., Ltd., Tokyo, Japan) and reverse transcribed using a reverse transcription system (Promega Corp., Madison, WI) according to the manufacturer's instructions. RT-PCR was performed with an ABI PRISM 7300 (PE Applied Biosystems, Foster City, CA). The sequences of the primers and probes are shown in Table I , and those for IFNAR1, IFNAR2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were purchased from Applied Biosystems.
Western blotting. HCC cells were cultured with various concentrations of 5-FU or IFN-·. Total protein was extracted using protein extraction reagent (M-PER™, Pierce, Rockford, IL) supplemented with protease inhibitors (Halt™ protease inhibitor cocktail kit, Pierce). Cell lysates were subjected to SDS-PAGE and transferred to Immobilon-P transfer membranes (Millipore, Bedford, MA). After blocking, membranes were probed with anti-TS, -OPRT and -TP monoclonal and anti-DPD polyclonal antibodies (a gift from TAIHO Pharmaceutical Co., Ltd., Tokyo, Japan), monoclonal antibody against TK (abcam, Cambridge, UK), polyclonal antibodies against IFNAR1, IFNAR2 and UP (Santa Cruz Biotechnology, Santa Cruz, CA). The proteins were visualized using HRP-conjugated antibodies followed by enhanced chemiluminescence (Pierce). The intensity of luminescence was quantified using an image analysis system (LAS-1000, Fuji Film, Tokyo, Japan). 
Results

Antiproliferative effects of IFN-· and 5-FU in six HCC cell lines.
When the antiproliferative effects of IFN-· and 5-FU on six HCC cell lines were examined, the growth inhibition seen Table I . Probe and primer pair sequences for six factors regulating 5-FU sensitivity.
Forward primer: 5'-GAATCACATCGAGCCACTGAAA-3' Reverse primer:
5'-CAGCCCAACCCCTAAAGACTGA-3'
Probe:
Forward primer: 5'-AATGATTCGAAGAGCTTTTGAAGC-3' Reverse primer:
5'-GTTCCCCGGATGATTCTGG-3'
Forward primer: 5'-TCCTGGGCAGATCTAGTAAATGC-3' Reverse primer:
5'-TGCTCCTCAGCCATTCTAACC-3'
Forward primer: 5'-CCTGCGGACGGAATCCT-3' Reverse primer:
5'-GCTGTGATGAGTGGCAGGCT-3'
Forward primer: 5'-TGACTGCCCAGGTAGAGACTATCC-3' Reverse primer:
5'-AGACCTATCCCACCAGAAGTGC-3'
Forward primer: - in all HCC cell lines was dose-dependent ( Fig. 1) . The HCC cell lines showed varied sensitivities to IFN-·, with IC 50 values over a 25-fold range, from 19 to 700 IU/ml (Table II) Table II shows the relative levels of basal mRNAs for IFNAR1, IFNAR2 and factors regulating sensitivity to 5-FU, with an arbitrary maximum value of 100. The mRNA levels of IFNAR1 were highest in Table II . Relative mRNA expression levels of type I IFN receptor subunits and six factors regulating sensitivity to 5-FU in six HCC cell lines. --------------------------------------------------------------------------------------------------- - the IFN-·-sensitive cell lines HAK-1B and KYN-1, while those in the other four HCC lines, which included both IFN-·-sensitive and resistant lines, were only 5-40% of their levels in HAK-1B. As for IFNAR-1, the levels of IFNAR-2 mRNA were relatively higher in HAK-1B and KYN-1. Moreover, both IFN-·-resistant cell lines, HAK-1A and KYN-2, had relatively lower levels of IFNAR-1 and IFNAR-2 mRNAs, while the other IFN-·-sensitive cell lines had relatively higher levels of mRNA for both subunits. Of the six factors regulating sensitivity to 5-FU, low levels of TS and DPD and high levels of OPRT, TP, UP and TK render cancer cells sensitive to 5-FU in in vitro assays. Cellular TS mRNA levels were relatively high in two 5-FUresistant lines, KYN-1 and KYN-3, while DPD mRNA levels were high only in KYN-1 cells. Cellular TP mRNA levels were relatively low in the 5-FU-resistant KYN-1, but high in the 5-FU-sensitive HAK-1B cells. However, overall there was no clear association between the cellular mRNA levels of each factor and the 5-FU sensitivity of the six HCC lines.
Combined effect of IFN-· and 5-FU on six HCC cell lines.
The isobologram method yielded three curves, Mode I, Mode IIa and Mode IIb. All of the data points for combined treatments against KYN-1 and KYN-2 cell lines, and three out of six data points for HAK-1A, fell in the area suggesting a synergistic effect and the other three points for HAK-1A cells were almost on the mode I curve ( Fig. 2A and C) . Therefore the combined effect of IFN-· and 5-FU on these three cell lines was judged to be synergistic. By contrast, all of the data points for combined treatments of HAK-1B, KYN-3, and KIM-1 cells fell within the envelope of additivity, and the combined effects on these cell lines were judged to be additive (Fig. 2D and F) . Based on these results, we separated the six cell lines into two groups: the S-group, showing synergistic responses, and consisting of KYN-1, KYN-2, and HAK-1A, and the A-group, characterized by additive responses, and consisting of HAK-1B, KYN-3, and KIM-1.
As shown in Fig. 3 , schedule-dependent interactions between IFN-· and 5-FU were examined using KYN-1 cells showing synergistic effect with simultaneous treatment of IFN-· and 5-FU. Sequential exposure to 5-FU followed by IFN-· showed much stronger antiproliferative effect than the reverse sequence at all tested concentration sets of 5-FU and IFN-·. Fig. 4A . The antitumor effects of 5-FU primarily depend on levels of its metabolic enzymes in in vitro study. We selected six enzymes, TS, DPD, OPRT, TP, UP and TK, that were reported to be closely associated with sensitivity and/or resistance to 5-FU. We examined their protein levels in these six cell lines when treated with IFN-· at 500 IU/ml for 48 h (Fig. 4B) . The expression levels of TS, OPRT and TK were down-regulated after treatment with IFN-· for 48 h, not only cell lines in the S-group, but also in the A-group. By contrast, treatment with IFN-· resulted in a 3-fold increase in DPD protein level in KYN-3 cells. We also observed an upregulation of TP in IFN-· treated KYN-1 and HAK-1A cells, both in the S-group, by 6.9-and 2.8-fold respectively. However, none of the six factors regulating sensitivity to 5-FU was consistently modulated in response to IFN-· in all of the S-group or all of the A-group cell lines. (Fig. 5A) . By contrast, there appeared only a slight or no increase in IFNAR-1 mRNA in KIM-1, KYN-3, and HAK-1B in the A-group. We observed a 2.5-to 3-fold increase in IFNAR2 mRNA in KYN-1 and HAK-1A, but not in KYN-2 in the S-group by 5-FU. By contrast, there appeared no increase of IFNAR2 mRNA by 5-FU in KIM-1, KYN-3, and HAK-1B cells in the A-group (Fig. 5B) . Time-dependent kinetics for the expression of both type I IFN receptor subunits showed a marked increase in IFNAR1 and IFNAR2 mRNA levels at 3 h in KYN-1 cells, but not in KYN-3 cells when treated with 5-FU (Fig. 6A and B) . In KYN-1 cells, Western blot analysis also showed an approximate 4-fold increase in protein levels of IFNAR1, 24 h after exposure to 5-FU (Fig. 6C) . Treatment of KYN-1 cells with 5-FU induced an approximate 7-fold increase in IFNAR2 protein.
Effect of IFN-· on protein expression of factors regulating 5-FU sensitivity. The metabolism of 5-FU is shown in
Effect of 5-FU
In contrast, in KYN-3 cells in the A-group, the levels of the IFNAR2-related molecules R2 were not increased by 5-FU treatment (Fig. 6D) .
Effect of knockdown of IFNAR1 and IFNAR2 by siRNA on antiproliferative effect of IFN-·.
We next examined whether cellular levels of IFNAR1 and/or IFNAR2 were closely associated with IFN-·-induced antiproliferative effect in KYN-1 and KYN-3. Cellular levels of IFNAR1 and IFNAR2 proteins were markedly reduced by the relevant siRNAs, but not by scrambled RNAs (Fig. 7A) . Moreover, the antiproliferative effect of IFN-· on both KYN-1 and KYN-3 cells was abrogated by knockdown of either IFNAR1 or IFNAR2, while the scrambled RNAs had no effect (Fig. 7B) . Quantitative analysis of the cell survival curves of KYN-1 revealed that the knockdown of IFNAR1 and IFNAR2 increased the IC 50 values for IFN-·, by 7-fold (231 IU/ml) and 5-fold (158 IU/ml) respectively, compared to the IC 50 values (31 IU/ml) for cells untreated with siRNAs and treated with scramble RNAs (Fig. 7C and Table III ). In KYN-3 cells, the knockdown of IFNAR1 and IFNAR2 increased the IC 50 values for IFN-· from 21 IU/ml for untreated control cells to over 1000 IU/ml respectively. The antiproliferative activity of IFN-· in KYN-1 and KYN-3 cells was thus confirmed to be dependent on the expression levels of both IFNAR1 and IFNAR2.
Discussion
In this study, six independently established HCC cell lines were subjected to simultaneous treatment with 5-FU and IFN-· and classified into two groups on the basis of their antiproliferative activity according to isobologram analysis: KYN-1, KYN-2 and HAK-1A, in which the two drugs had a synergistic effect, were in the S-group, and HAK-1B, KYN-3 and KIM-1, in which the two drugs had an additive effect, were in the A-group. We further asked whether treatment with either 5-FU or IFN-· could modulate the expression of factors likely to be involved in the classification of the HCC cell lines into the S-or A-group.
We first determined cellular levels of mRNA and protein of TS, DPD, OPRT, TP, UP, and TK genes that are known to be involved in sensitivity to 5-FU (Table II and Fig. 4B ). Basal levels of these cellular proteins in six cell lines used in this study were found to be comparable to their mRNA levels of these six enzymes. We examined whether exposure to IFN-· could modulate the protein expression levels of these six genes. Cellular expression levels of TS were not significantly different in cell lines of the S-and A-group, suggesting that TS might not be a critical factor determining whether the combination effect is synergic or additive. None 
The IFNARs genes were silenced by Stealth™ RNAi (Invitrogen™ Life Technologies). KYN-1 and KYN-3 cells were treated with siRNAs and exposed to IFN-· for 5 days. IC 50 values were calculated from dose-response curves shown in Fig. 7C .
of the other genes were specifically down-or up-regulated in a similar manner in the 3 cell lines of the S-or A-group.
We next examined whether exposure to 5-FU could modulate expression levels of both mRNA and protein of IFNAR1 and IFNAR2. Knock down of IFNAR1 or IFNAR2 gene by its specific siRNA markedly desensitized the sensitivity of hepatic cancer cells to IFN-·. This suggested that both IFNAR1 and IFNAR2 are closely associated with antiproliferative effect by IFN-·. We further observed an approximate 4-fold increase in mRNA of IFNAR1 in the three cell lines in the S group, but no increase in the three cell lines in the Agroup, when treated with 5-FU. Western blot analysis showed an approximate 4-fold increase in IFNAR1 in a time-dependent manner and an approximate 7-fold increase in IFNAR2 in 5-FU-treated KYN-1 cells, but not in KYN-3. Treatment with 5-FU thus could induce specific expression of both IFNAR1 and IFNAR2 in HCC cell lines in the S-group, but not in the A-group. A relevant study by Kondo has reported that a combination of IFN-· and 5-FU strongly induced apoptosis in HCC cells in association with Bcl-2 family members by activation of IFNAR2 signal (33) . Ota and colleagues have recently demonstrated a significant correlation of IFNAR2 expression and response rates in patients with HCC when treated with a combination of IFN-· and 5-FU (6). Collectively, Table III. C up-regulation of IFNAR1 and IFNAR2 by 5-FU might play a pivotal role in synergism of IFN-· combined with 5-FU against HCC.
In conclusion, we present a novel finding that synergy between 5-FU and IFN-· in HCC cells is mediated through the 5-FU-induced up-regulation of the type I IFN receptor. The translation of this in vitro result into clinical application, particularly the identification of whether or not 5-FU upregulates the type I IFN receptor in a specific patient, would have a tremendous impact on the selection of the best treatment modality. Practical methods for determining the up-regulation of the type I IFN receptor, for selecting responders to combined IFN-· and 5-FU therapy should be the subject of further research. Moreover, our assay system using HCC cell lines could provide novel insights of practical significance, about other anticancer agents besides 5-FU, which could efficiently up-regulate the expression of the type I IFN receptor.
